Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Mechanisms of Resistance

IMP-51, a Novel IMP-Type Metallo-β-Lactamase with Increased Doripenem- and Meropenem-Hydrolyzing Activities, in a Carbapenem-Resistant Pseudomonas aeruginosa Clinical Isolate

Tatsuya Tada, Pham Hong Nhung, Tohru Miyoshi-Akiyama, Kayo Shimada, Doan Mai Phuong, Nguyen Quoc Anh, Norio Ohmagari, Teruo Kirikae
Tatsuya Tada
aDepartment of Infectious Diseases, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pham Hong Nhung
dDepartment of Microbiology, Hanoi Medical University, Hanoi, Vietnam
eBach Mai Hospital, Hanoi, Vietnam
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tohru Miyoshi-Akiyama
bPathogenic Microbe Laboratory, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kayo Shimada
aDepartment of Infectious Diseases, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Doan Mai Phuong
eBach Mai Hospital, Hanoi, Vietnam
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nguyen Quoc Anh
eBach Mai Hospital, Hanoi, Vietnam
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Norio Ohmagari
cDisease Control and Prevention Center, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Teruo Kirikae
aDepartment of Infectious Diseases, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.01611-15
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

A meropenem-resistant Pseudomonas aeruginosa isolate was obtained from a patient in a medical setting in Hanoi, Vietnam. The isolate was found to have a novel IMP-type metallo-β-lactamase, IMP-51, which differed from IMP-7 by an amino acid substitution (Ser262Gly). Escherichia coli expressing blaIMP-51 showed greater resistance to cefoxitin, meropenem, and moxalactam than E. coli expressing blaIMP-7. The amino acid residue at position 262 was located near the active site, proximal to the H263 Zn(II) ligand.

TEXT

Metallo-β-lactamases (MBLs) confer resistance to all β-lactams, except for monobactams, and are characterized by their efficient hydrolysis of carbapenems (1). Acquired MBLs are produced by Gram-negative bacteria, including Pseudomonas aeruginosa, Acinetobacer spp., and enterobacteria (1). The acquired MBLs are categorized by their amino acid sequences into various types (2–4), including AIM (5), DIM (6), FIM (7), GIM (8), IMPs (9), KHM (10), NDMs (11), SMB (12), SIM (13), SPM (14), TMBs (15) and VIMs (16). The most prevalent types of MBLs are the IMP-, VIM-, and NDM-type enzymes (1, 2, 17). We describe here a novel IMP-type MBL, IMP-51, produced by a clinical isolate of P. aeruginosa in a medical setting in Vietnam.

The P. aeruginosa clinical isolate NCGM3025 was obtained from a sputum sample of a patient in 2013 in an intensive care unit in a medical setting in Hanoi, Vietnam. MICs of various antibiotics were determined using the microdilution method, according to the guidelines of the Clinical and Laboratory Standards Institute (18). IMP-type MBLs and an aminoglycoside modification enzyme, AAC(6′)-Ib, were detected using immunochromatographic assay kits (19, 20). DNA was extracted from the isolate using DNeasy blood and tissue kits (Qiagen, Tokyo, Japan), and the entire genome was sequenced by MiSeq (Illumina, San Diego, CA). Sequence data were analyzed using CLC Genomics Workbench version 8.0 (CLC bio, Tokyo, Japan). Multilocus sequence typing (MLST) was deduced as described by the protocols of the PubMLST databases (http://pubmlst.org/paeruginosa/). Sequences of drug resistance genes, including β-lactamase-encoding genes at the Lahey Clinic website (www.lahey.org/studies), aminoglycoside, chloramphenicol, and fosfomycin resistance genes registered in GenBank (http://www.ncbi.nlm.nih.gov/nuccore/), and quinolone resistance genes (21), were determined using CLC Genomics Workbench version 8.0.

Escherichia coli transformants expressing blaIMP-7 and blaIMP-51 were produced, and the recombinant IMP-7 and IMP-51 were purified as previously described (22). During the purification process, β-lactamase activity was monitored using nitrocefin (Oxoid Ltd., Basingstoke, United Kingdom). The initial rate of hydrolysis in 50 mM Tris-HCl (pH 7.4), 0.3 M NaCl, and 10 μM Zn(NO3)2 at 37°C was determined by UV-visible spectrophotometry (V-530; Jasco, Tokyo, Japan), with the reaction initiated by the addition of substrate into spectrophotometer cells, and UV absorption measured during the initial phase of the reaction. Km, kcat, and the kcat/Km ratio were determined using a Hanes-Woolf plot. Wavelengths and extinction coefficients were used for the analysis of β-lactam substrates (23–25). Km and kcat were determined using triplicate analyses.

A DNA plug of NCGM3025, digested with I-CeuI, was prepared, separated by pulsed-field gel electrophoresis, and subjected to Southern hybridization (26) using 16S rRNA and blaIMP-51 probes (12, 27).

P. aeruginosa NCGM3025 was resistant to all antibiotics tested, except for amikacin, colistin, and tigecycline. The isolate was susceptible to amikacin and intermediate to colistin and tigecycline. The MICs of β-lactams in NCGM3025 are shown in Table 1; the MICs of other antibiotics were 16 μg/ml for arbekacin, 16 μg/ml for amikacin, 1 μg/ml for colistin, 64 μg/ml for gentamicin, 16 μg/ml for ciprofloxacin, >1,024 μg/ml for fosfomycin, and 4 μg/ml for tigecycline. NCGM3025 was positive for IMP-type MBLs and AAC(6′)-Ib. Whole-genome sequencing revealed that the isolate had a novel blaIMP variant, designated blaIMP-51. Its predicted amino acid sequence revealed that IMP-51 differed from IMP-7 by an amino acid substitution (Ser262Gly) and from IMP-43 by two amino acid substitutions (Phe67Val and Ser262Gly). A phylogenetic tree showed that IMP-51 belonged to an IMP-7-like clade (Fig. 1). In addition to blaIMP-51, NCGM3025 had several drug resistance genes, including aac(6′)-Ib-cr, aac(6′)-Ib, aph(3′)-IIb, blaPAO, blaOXA-246, blaOXA-50, cmlA1, catB7, and fosA. The isolate had a point mutation in the quinolone-resistance-determining region of gyrA with an amino acid substitution of Ser83Ile in GyrA. The MLST of NCGM3025 was sequence type 235 (ST235).

View this table:
  • View inline
  • View popup
TABLE 1

MICs of β-lactams for P. aeruginosa NCGM3025 and E. coli transformants containing blaIMP-7 and blaIMP-51

FIG 1
  • Open in new tab
  • Download powerpoint
FIG 1

Dendrogram of 45 IMP-type MBLs for comparison with IMP-51. The dendrogram was calculated with the Clustal W2 program. Branch lengths correspond to the number of amino acid exchanges for IMP-type enzymes.

E. coli DH5α, expressing blaIMP-7 or blaIMP-51, showed a significant reduction in susceptibility to all tested β-lactams, except for aztreonam, compared with DH5α expressing a vector control (Table 1). E. coli DH5α expressing blaIMP-51 showed 4-fold higher MICs of cefoxitin, meropenem, and moxalactam, 4-fold lower MICs of ampicillin, ampicillin-sulbactam, penicillin G, cefpirome, and ceftazidime, and 8-fold lower MICs of cephradine than E. coli DH5α expressing blaIMP-7 (Table 1).

Recombinant IMP-7 and IMP-51 hydrolyzed all tested β-lactams, except for aztreonam (Table 2). IMP-51 showed markedly higher kcat/Km ratios for cefmetazole, cefotaxime, cefoxitin, doripenem, meropenem, and moxalactam and lower kcat/Km ratios for ampicillin, penicillin G, cefpirome, ceftazidime, cephradine, imipenem, and panipenem. In particular, the higher kcat values of IMP-51 than those of IMP-7 for doripenem and meropenem resulted in the higher kcat/Km ratios for IMP-51 (Table 2). The kcat/Km values of IMP-51 against cefepime were similar to those of IMP-7 (Table 2).

View this table:
  • View inline
  • View popup
TABLE 2

Kinetic parameters of IMP-7 and IMP-51 enzymesa

The differences of the kcat/Km values between IMP-7 and IMP-51 were well-correlated to those of the MICs of antibiotics between E. coli expressing blaIMP-7 and E. coli expressing blaIMP-51. Compared with IMP-7, IMP-51, which showed higher kcat/Km ratios for cefotaxime, cefoxitin, doripenem, meropenem, and moxalactam, conferred higher MICs for these antibiotics in E. coli, whereas IMP-51, which showed lower kcat/Km ratios for ampicillin, penicillin G, cefpirome, ceftazidime, and cephradine, conferred lower MICs for these antibiotics in E. coli (Table 1 and 2).

The sequence surrounding blaIMP-51 was determined to be tnpA-tnpR-intI1-blaIMP-51-aac(6′)-Ib-aac(6′)-cmlA1-blaOXA-246 (9,797 bp), which was obtained from a contig assembled by Genomic Workbench. The blaIMP-51 gene was located within a class I integron, of which the downstream region was not determined because it was not contained in the sequence of the contig. The genetic structure that included blaIMP-51 had a unique gene cassette array and was located on the chromosome by Southern hybridization (data not shown). In the structure, tnpA-tnpR (nucleotide 1 [nt 1] to nt 5,059) was identical to the sequence of the Tn1403-like transposon in a plasmid pOZ176 from P. aeruginosa PA96 isolated in China (28). The cmlA1-blaOXA-246 (nt 7,321 to nt 9,786) was similar to a part of the DK45-2 class 1 integron (nt 669 to nt 3,134) in P. aeruginosa DK45 isolated in South Korea (GenBank accession number GQ853420). The blaOXA-246 was first identified in a plasmid from P. aeruginosa pae943 isolated in China (GenBank accession number EU886980).

The Ser262Gly substitution in IMP-51 markedly affected the catalytic activities of the enzyme against β-lactams, especially against carbapenems. IMP-51 had higher kcat/Km ratios against doripenem and meropenem but lower kcat/Km ratios against imipenem and panipenem than those of IMP-7. These differences in catalytic activities may explain the high resistance of NCGM3025 against doripenem and meropenem (Table 1). Similarly, IMP-6 with a Ser262Gly substitution had higher activity against meropenem and panipenem than that of IMP-1 (29). Residue 262 is located near the Zn(II) binding site, which plays an important role in β-lactam turnover catalyzed by IMP-type MBLs (30). The Ser262Gly substitution in IMP-6 compared with that in IMP-1 (29) was found to stabilize the anionic intermediate of certain β-lactam substrates bound to IMP-6, enhancing catalysis (31).

In conclusion, a doripenem- and meropenem-resistant P. aeruginosa isolate producing IMP-51 has emerged in Vietnam. The Ser262Gly amino acid substitution in IMP-51 appeared to significantly increase its hydrolytic activity for doripenem and meropenem. This substitution may have arisen due to the selective pressure caused by the use of doripenem and meropenem.

Nucleotide sequence accession number.The genomic environment surrounding blaIMP-51 was identified and deposited in GenBank under the accession number LC031883.

ACKNOWLEDGMENTS

This study was approved by the Bach Mai Hospital institutional review board (approval no. 38) and the Biosafety Committee at the National Center for Global Health and Medicine.

The study was supported by grants from International Health Cooperation Research (no. 27-S-1102 and 26-A-103) and a grant from the Research Program on Emerging and Reemerging Infectious Diseases from Japan Agency for Medical Research and Development (AMED).

FOOTNOTES

    • Received 8 July 2015.
    • Returned for modification 31 July 2015.
    • Accepted 10 August 2015.
    • Accepted manuscript posted online 17 August 2015.
  • Copyright © 2015, American Society for Microbiology. All Rights Reserved.

REFERENCES

  1. 1.↵
    1. Bush K
    . 2001. New β-lactamases in Gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy. Clin Infect Dis 32:1085–1089. doi:10.1086/319610.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Walsh TR,
    2. Toleman MA,
    3. Poirel L,
    4. Nordmann P
    . 2005. Metallo-β-lactamases: the quiet before the storm? Clin Microbiol Rev 18:306–325. doi:10.1128/CMR.18.2.306-325.2005.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Bush K,
    2. Jacoby GA
    . 2010. Updated functional classification of β-lactamases. Antimicrob Agents Chemother 54:969–976. doi:10.1128/AAC.01009-09.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Cornaglia G,
    2. Giamarellou H,
    3. Rossolini GM
    . 2011. Metallo-β-lactamases: a last frontier for β-lactams? Lancet Infect Dis 11:381–393. doi:10.1016/S1473-3099(11)70056-1.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    1. Yong D,
    2. Toleman MA,
    3. Bell J,
    4. Ritchie B,
    5. Pratt R,
    6. Ryley H,
    7. Walsh TR
    . 2012. Genetic and biochemical characterization of an acquired subgroup B3 metallo-β-lactamase gene, blaAIM-1, and its unique genetic context in Pseudomonas aeruginosa from Australia. Antimicrob Agents Chemother 56:6154–6159. doi:10.1128/AAC.05654-11.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Rogalski TM,
    2. Gilbert MM,
    3. Devenport D,
    4. Norman KR,
    5. Moerman DG
    . 2003. DIM-1, a novel immunoglobulin superfamily protein in Caenorhabditis elegans, is necessary for maintaining bodywall muscle integrity. Genetics 163:905–915.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Pollini S,
    2. Maradei S,
    3. Pecile P,
    4. Olivo G,
    5. Luzzaro F,
    6. Docquier JD,
    7. Rossolini GM
    . 2013. FIM-1, a new acquired metallo-β-lactamase from a Pseudomonas aeruginosa clinical isolate from Italy. Antimicrob Agents Chemother 57:410–416. doi:10.1128/AAC.01953-12.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Castanheira M,
    2. Toleman MA,
    3. Jones RN,
    4. Schmidt FJ,
    5. Walsh TR
    . 2004. Molecular characterization of a β-lactamase gene, blaGIM-1, encoding a new subclass of metallo-β-lactamase. Antimicrob Agents Chemother 48:4654–4661. doi:10.1128/AAC.48.12.4654-4661.2004.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Osano E,
    2. Arakawa Y,
    3. Wacharotayankun R,
    4. Ohta M,
    5. Horii T,
    6. Ito H,
    7. Yoshimura F,
    8. Kato N
    . 1994. Molecular characterization of an enterobacterial metallo-β-lactamase found in a clinical isolate of Serratia marcescens that shows imipenem resistance. Antimicrob Agents Chemother 38:71–78. doi:10.1128/AAC.38.1.71.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Sekiguchi J,
    2. Morita K,
    3. Kitao T,
    4. Watanabe N,
    5. Okazaki M,
    6. Miyoshi-Akiyama T,
    7. Kanamori M,
    8. Kirikae T
    . 2008. KHM-1, a novel plasmid-mediated metallo-β-lactamase from a Citrobacter freundii clinical isolate. Antimicrob Agents Chemother 52:4194–4197. doi:10.1128/AAC.01337-07.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Yong D,
    2. Toleman MA,
    3. Giske CG,
    4. Cho HS,
    5. Sundman K,
    6. Lee K,
    7. Walsh TR
    . 2009. Characterization of a new metallo-β-lactamase gene, blaNDM-1, and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother 53:5046–5054. doi:10.1128/AAC.00774-09.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Wachino J,
    2. Yoshida H,
    3. Yamane K,
    4. Suzuki S,
    5. Matsui M,
    6. Yamagishi T,
    7. Tsutsui A,
    8. Konda T,
    9. Shibayama K,
    10. Arakawa Y
    . 2011. SMB-1, a novel subclass B3 metallo-β-lactamase, associated with ISCR1 and a class 1 integron, from a carbapenem-resistant Serratia marcescens clinical isolate. Antimicrob Agents Chemother 55:5143–5149. doi:10.1128/AAC.05045-11.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Lee K,
    2. Yum JH,
    3. Yong D,
    4. Lee HM,
    5. Kim HD,
    6. Docquier JD,
    7. Rossolini GM,
    8. Chong Y
    . 2005. Novel acquired metallo-β-lactamase gene, blaSIM-1, in a class 1 integron from Acinetobacter baumannii clinical isolates from Korea. Antimicrob Agents Chemother 49:4485–4491. doi:10.1128/AAC.49.11.4485-4491.2005.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Zavascki AP,
    2. Gaspareto PB,
    3. Martins AF,
    4. Goncalves AL,
    5. Barth AL
    . 2005. Outbreak of carbapenem-resistant Pseudomonas aeruginosa producing SPM-1 metallo-β-lactamase in a teaching hospital in southern Brazil. J Antimicrob Chemother 56:1148–1151. doi:10.1093/jac/dki390.
    OpenUrlCrossRefPubMedWeb of Science
  15. 15.↵
    1. El Salabi A,
    2. Borra PS,
    3. Toleman MA,
    4. Samuelsen O,
    5. Walsh TR
    . 2012. Genetic and biochemical characterization of a novel metallo-β-lactamase, TMB-1, from an Achromobacter xylosoxidans strain isolated in Tripoli, Libya. Antimicrob Agents Chemother 56:2241–2245. doi:10.1128/AAC.05640-11.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Lauretti L,
    2. Riccio ML,
    3. Mazzariol A,
    4. Cornaglia G,
    5. Amicosante G,
    6. Fontana R,
    7. Rossolini GM
    . 1999. Cloning and characterization of blaVIM, a new integron-borne metallo-β-lactamase gene from a Pseudomonas aeruginosa clinical isolate. Antimicrob Agents Chemother 43:1584–1590.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Jacoby GA,
    2. Munoz-Price LS
    . 2005. The new β-lactamases. N Engl J Med 352:380–391. doi:10.1056/NEJMra041359.
    OpenUrlCrossRefPubMedWeb of Science
  18. 18.↵
    Clinical and Laboratory Standards Institute. 2015. Performance standards for antimicrobial susceptibility testing; 25th informational supplement. CLSI M100-S25. Clinical and Laboratory Standards Institute, Wayne, PA.
  19. 19.↵
    1. Kitao T,
    2. Miyoshi-Akiyama T,
    3. Tanaka M,
    4. Narahara K,
    5. Shimojima M,
    6. Kirikae T
    . 2011. Development of an immunochromatographic assay for diagnosing the production of IMP-type metallo-β-lactamases that mediate carbapenem resistance in Pseudomonas. J Microbiol Methods 87:330–337. doi:10.1016/j.mimet.2011.09.011.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Tada T,
    2. Miyoshi-Akiyama T,
    3. Tanaka M,
    4. Narahara K,
    5. Shimojima M,
    6. Kitao T,
    7. Shimada K,
    8. Kirikae T
    . 2012. Development of an immunochromatographic assay for rapid detection of AAC(6′)-Ib-producing Pseudomonas aeruginosa. J Microbiol Methods 91:114–116. doi:10.1016/j.mimet.2012.05.009.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Sekiguchi J,
    2. Asagi T,
    3. Miyoshi-Akiyama T,
    4. Kasai A,
    5. Mizuguchi Y,
    6. Araake M,
    7. Fujino T,
    8. Kikuchi H,
    9. Sasaki S,
    10. Watari H,
    11. Kojima T,
    12. Miki H,
    13. Kanemitsu K,
    14. Kunishima H,
    15. Kikuchi Y,
    16. Kaku M,
    17. Yoshikura H,
    18. Kuratsuji T,
    19. Kirikae T
    . 2007. Outbreaks of multidrug-resistant Pseudomonas aeruginosa in community hospitals in Japan. J Clin Microbiol 45:979–989. doi:10.1128/JCM.01772-06.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Tada T,
    2. Shrestha B,
    3. Miyoshi-Akiyama T,
    4. Shimada K,
    5. Ohara H,
    6. Kirikae T,
    7. Pokhrel BM
    . 2014. NDM-12, a novel New Delhi metallo-β-lactamase variant from a carbapenem-resistant Escherichia coli clinical isolate in Nepal. Antimicrob Agents Chemother 58:6302–6305. doi:10.1128/AAC.03355-14.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Boschi L,
    2. Mercuri PS,
    3. Riccio ML,
    4. Amicosante G,
    5. Galleni M,
    6. Frere JM,
    7. Rossolini GM
    . 2000. The Legionella (Fluoribacter) gormanii metallo-β-lactamase: a new member of the highly divergent lineage of molecular-subclass B3 β-lactamases. Antimicrob Agents Chemother 44:1538–1543. doi:10.1128/AAC.44.6.1538-1543.2000.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. Crowder MW,
    2. Walsh TR,
    3. Banovic L,
    4. Pettit M,
    5. Spencer J
    . 1998. Overexpression, purification, and characterization of the cloned metallo-β-lactamase L1 from Stenotrophomonas maltophilia. Antimicrob Agents Chemother 42:921–926.
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    1. Queenan AM,
    2. Shang W,
    3. Flamm R,
    4. Bush K
    . 2010. Hydrolysis and inhibition profiles of β-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. Antimicrob Agents Chemother 54:565–569. doi:10.1128/AAC.01004-09.
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    1. Liu SL,
    2. Hessel A,
    3. Sanderson KE
    . 1993. Genomic mapping with I-Ceu I, an intron-encoded endonuclease specific for genes for ribosomal RNA, in Salmonella spp., Escherichia coli, and other bacteria. Proc Natl Acad Sci U S A 90:6874–6878. doi:10.1073/pnas.90.14.6874.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    1. Tada T,
    2. Miyoshi-Akiyama T,
    3. Shimada K,
    4. Kirikae T
    . 2014. Biochemical analysis of the metallo-β-lactamase NDM-3 from a multidrug-resistant Escherichia coli strain isolated in Japan. Antimicrob Agents Chemother 58:3538–3540. doi:10.1128/AAC.02793-13.
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    1. Xiong J,
    2. Alexander DC,
    3. Ma JH,
    4. Deraspe M,
    5. Low DE,
    6. Jamieson FB,
    7. Roy PH
    . 2013. Complete sequence of pOZ176, a 500-kilobase IncP-2 plasmid encoding IMP-9-mediated carbapenem resistance, from outbreak isolate Pseudomonas aeruginosa 96. Antimicrob Agents Chemother 57:3775–3782. doi:10.1128/AAC.00423-13.
    OpenUrlAbstract/FREE Full Text
  29. 29.↵
    1. Yano H,
    2. Kuga A,
    3. Okamoto R,
    4. Kitasato H,
    5. Kobayashi T,
    6. Inoue M
    . 2001. Plasmid-encoded metallo-β-lactamase (IMP-6) conferring resistance to carbapenems, especially meropenem. Antimicrob Agents Chemother 45:1343–1348. doi:10.1128/AAC.45.5.1343-1348.2001.
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    1. Pegg KM,
    2. Liu EM,
    3. George AC,
    4. LaCuran AE,
    5. Bethel CR,
    6. Bonomo RA,
    7. Oelschlaeger P
    . 2014. Understanding the determinants of substrate specificity in IMP family metallo-β-lactamases: the importance of residue 262. Protein Sci 23:1451–1460. doi:10.1002/pro.2530.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Oelschlaeger P,
    2. Schmid RD,
    3. Pleiss J
    . 2003. Modeling domino effects in enzymes: molecular basis of the substrate specificity of the bacterial metallo-β-lactamases IMP-1 and IMP-6. Biochemistry 42:8945–8956. doi:10.1021/bi0300332.
    OpenUrlCrossRefPubMed
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
IMP-51, a Novel IMP-Type Metallo-β-Lactamase with Increased Doripenem- and Meropenem-Hydrolyzing Activities, in a Carbapenem-Resistant Pseudomonas aeruginosa Clinical Isolate
Tatsuya Tada, Pham Hong Nhung, Tohru Miyoshi-Akiyama, Kayo Shimada, Doan Mai Phuong, Nguyen Quoc Anh, Norio Ohmagari, Teruo Kirikae
Antimicrobial Agents and Chemotherapy Oct 2015, 59 (11) 7090-7093; DOI: 10.1128/AAC.01611-15

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
IMP-51, a Novel IMP-Type Metallo-β-Lactamase with Increased Doripenem- and Meropenem-Hydrolyzing Activities, in a Carbapenem-Resistant Pseudomonas aeruginosa Clinical Isolate
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
IMP-51, a Novel IMP-Type Metallo-β-Lactamase with Increased Doripenem- and Meropenem-Hydrolyzing Activities, in a Carbapenem-Resistant Pseudomonas aeruginosa Clinical Isolate
Tatsuya Tada, Pham Hong Nhung, Tohru Miyoshi-Akiyama, Kayo Shimada, Doan Mai Phuong, Nguyen Quoc Anh, Norio Ohmagari, Teruo Kirikae
Antimicrobial Agents and Chemotherapy Oct 2015, 59 (11) 7090-7093; DOI: 10.1128/AAC.01611-15
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • TEXT
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596